PT-141 (bremelanotide, brand name Vyleesi) is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. Its mechanism differs from every other compound discussed in this series.
Central action, not peripheral action
PT-141 acts centrally through melanocortin pathways, rather than peripherally through vascular or tissue mechanisms. Specifically, it activates melanocortin-3 and melanocortin-4 receptors in the hypothalamus and limbic system. These brain regions control sexual motivation, arousal, and reward. This is why it can influence sexual function even without direct physical stimulation.
PT-141 is also effective in patients who do not respond to PDE-5 inhibitors such as sildenafil. This makes it mechanistically distinct from traditional erectile dysfunction drugs.
FDA approval status
PT-141 has been approved by the FDA for hypoactive sexual desire disorder in premenopausal women. This makes it one of the few compounds in this class to have completed the regulatory approval process. The approval was based on data from multiple clinical trials. Although its mechanism involves shared melanocortin receptor pathways, use in men remains off-label.
Side effects cannot be ignored
As peptide use grows, PT-141’s side effects deserve particular attention. At standard doses, up to 40% of subjects experience nausea, 20% to 40% experience facial flushing, and transient blood pressure increases have been documented. Repeated use may also lead to reduced tolerance.
These data do not mean the compound is “bad.” Rather, they reveal the difference between clinical dosing and conditions versus real-world use of gray-market products. Self-administration without medical supervision clearly amplifies risk.
Conclusion
PT-141 is a uniquely mechanized, approved, but side-effect-heavy peptide. Understanding its central pathway and clinical boundaries is the prerequisite for a rational view.